In trading on Wednesday, shares of NovaCopper Inc. (NCQ) entered into oversold territory, changing hands as low as $0.9871 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In the case of NovaCopper Inc., the RSI reading has hit 27.6 — by comparison, the universe of metals and mining stocks covered by Metals Channel currently has an average RSI of 41.8, the RSI of Spot Gold is at 29.8, and the RSI of Spot Silver is presently 37.0. A bullish investor could look at NCQ's 27.6 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), NCQ's low point in its 52 week range is $0.9871 per share, with $2.08 as the 52 week high point — that compares with a last trade of $0.9999. NovaCopper Inc. shares are currently trading down about 4.8% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Financial Market Behavior, General Mills Earnings: Market Recon
Markets must choose now between the easy, the tense and the uncertain. What could possibly go wrong?
Del Frisco's to Be Acquired for $650 Million by Private-Equity Firm L Catterton
Del Frisco's is being acquired by private-equity firm L Catterton for $8 a share.
Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
Bristol-Myers Squibb shares slumped lower in pre-market trading Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.